Sumit Jamwal, PhD
Associate Research ScientistAbout
Research
Publications
2024
A review on polyamines as promising next-generation neuroprotective and anti-aging therapy
Arthur R, Jamwal S, Kumar P. A review on polyamines as promising next-generation neuroprotective and anti-aging therapy. European Journal Of Pharmacology 2024, 978: 176804. PMID: 38950837, DOI: 10.1016/j.ejphar.2024.176804.Peer-Reviewed Original ResearchCognitive dysfunctionNeurodegenerative disordersRegulation of gene expressionProgressive degeneration of neuronsProgrammed cell deathDegeneration of neuronsSymptomatic therapyPharmacological strategiesAnti-oxidative effectsAnti-aging therapyAverage ageProgressive degenerationNeuroprotective effectsLocomotor abnormalitiesIon channelsCell deathBiochemical activityGene expressionPopulation average ageTherapyMolecular mechanismsDisordersPolyamine supplementationDysfunctionAnti-aging effectsDopamine Transporter Deficiency Syndrome (DTDS)
Jamwal S, Gautam A. Dopamine Transporter Deficiency Syndrome (DTDS). 2024, 1-4. DOI: 10.1007/978-3-319-66816-1_452-1.Peer-Reviewed Original ResearchDopamine transporter deficiency syndromeDopamine transporterMovement disordersHuman dopamine transporterSLC6A3 geneBehavioral symptomsAmbiguous eventsEarly adolescenceSlow speechDisordersHyperkinetic movementsSLC6A3Choreiform movementsAdolescentsEarly childhoodAssociated with poor outcomesLater onsetHypokinetic movementsAffected individualsNon-specific symptomsSymptomsDevelopmental targetsEarly-onsetResting tremorRecurrent movement disordersNutraceuticals Unveiled a Multifaceted Neuroprotective Mechanisms for Parkinson’s Disease: Elixir for the Brain
Soni D, Jamwal S, Chawla R, Singh S, Singh D, Singh T, Khurana N, Kanwal A, Dureja H, Patil U, Singh R, Kumar P. Nutraceuticals Unveiled a Multifaceted Neuroprotective Mechanisms for Parkinson’s Disease: Elixir for the Brain. Food Reviews International 2024, ahead-of-print: 1-24. DOI: 10.1080/87559129.2024.2337766.Peer-Reviewed Original ResearchPre-clinicalGut-brain axisProtein ubiquitinationParkinson's diseaseMitochondrial dysfunctionSignaling pathwayMolecular mechanismsRelieve PD symptomsSymptoms of PDClinical trialsHealth benefits of nutraceuticalsBenefits of nutraceuticalsCustomized therapyClinical aspectsExpression of PDMediterranean dietNeurotransmitter imbalanceNeuroprotective mechanismsNeuroprotective potentialOxidative stressDiseasePD symptomsHealth benefitsSymptomsUbiquitin
2023
Bacillus Calmette–Guérin Vaccine Attenuates Haloperidol-Induced TD-like Behavioral and Neurochemical Alteration in Experimental Rats
Yedke N, Upadhayay S, Singh R, Jamwal S, Ahmad S, Kumar P. Bacillus Calmette–Guérin Vaccine Attenuates Haloperidol-Induced TD-like Behavioral and Neurochemical Alteration in Experimental Rats. Biomolecules 2023, 13: 1667. PMID: 38002349, PMCID: PMC10669047, DOI: 10.3390/biom13111667.Peer-Reviewed Original ResearchConceptsBCG vaccineTardive dyskinesiaOrofacial dyskinesiaNeurotransmitter levelsBacillus Calmette-Guérin (BCG) vaccineFirst-generation antipsychotic drugsManagement of TDOxidative stressLevels of HVACalmette-Guérin vaccineHyperkinetic movement disordersMajor pathophysiological mechanismsPro-apoptotic markersLong-term useBCG treatmentNeuroprotective effectsNeurochemical alterationsOrofacial dysfunctionPathophysiological mechanismsAntipsychotic medicationNeuromodulatory propertiesSuppress inflammationSingle administrationAntipsychotic drugsHaloperidol injectionAge-associated sex difference in the expression of mitochondria-based redox sensitive proteins and effect of pioglitazone in nonhuman primate brain
Jamwal S, Blackburn J, Elsworth J. Age-associated sex difference in the expression of mitochondria-based redox sensitive proteins and effect of pioglitazone in nonhuman primate brain. Biology Of Sex Differences 2023, 14: 65. PMID: 37770961, PMCID: PMC10540392, DOI: 10.1186/s13293-023-00551-6.Peer-Reviewed Original ResearchConceptsSubstantia nigraSex-dependent expressionPrimate brainAdult male monkeysCerebrospinal fluidMale monkeysPeroxisome proliferator-activated receptor gamma agonistProliferator-activated receptor gamma agonistsEffect of pioglitazoneWeeks of treatmentReceptor gamma agonistsGreater expressionAdult female monkeysNonhuman primate brainNovel neuroprotective treatmentAfrican green monkeysSex-based differencesOral pioglitazoneNeuroprotective treatmentPIO treatmentRisk factorsCNS disordersGamma agonistsPreclinical studiesParkinson's diseaseAnimal models of Huntington’s disease and their applicability to novel drug discovery and development
Upadhayay S, Jamwal S, Kumar P. Animal models of Huntington’s disease and their applicability to novel drug discovery and development. Expert Opinion On Drug Discovery 2023, 18: 527-538. PMID: 37042034, DOI: 10.1080/17460441.2023.2201493.Peer-Reviewed Original ResearchConceptsHD animal modelsAnimal modelsHuntington's diseaseNon-motor symptomsProgressive neurodegenerative disorderDrug therapyDisease progressionPreclinical phaseLoss of functionNeurodegenerative disordersClinical phaseDrug discoveryDiseaseNovel drug discoveryHuntingtin geneToxic gainCAG trinucleotide repeatDrugsProgressionHD geneEnormous progressionAn Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development
Upadhayay S, Yedke N, Rahi V, Singh S, Kumar S, Arora A, Chandolia P, Kaur P, Kumar M, Koshal P, Jamwal S, Kumar P. An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development. Neurochemical Research 2023, 48: 1631-1647. PMID: 36738367, DOI: 10.1007/s11064-023-03868-1.Peer-Reviewed Original ResearchConceptsMedium spiny neuronsAnimal modelsGABAergic medium spiny neuronsDisease modelsKey clinical manifestationsHuntington's disease modelsPathogenesis of diseaseWeb of ScienceClinical manifestationsPathophysiological mechanismsSpiny neuronsPreclinical studiesMotor impairmentLike symptomsTherapeutic targetExperimental animalsExcessive productionHuntington's diseaseOxidative stressDiseasePathogenic conditionsDrug discoveryMitochondrial functionFree radicalsNeurotoxin
2022
miRNA‐encapsulated abiotic materials and biovectors for cutaneous and oral wound healing: Biogenesis, mechanisms, and delivery nanocarriers
Dey A, Yousefiasl S, Kumar A, Moghaddam F, Rahimmanesh I, Samandari M, Jamwal S, Maleki A, Mohammadi A, Rabiee N, Paiva‐Santos A, Tamayol A, Sharifi E, Makvandi P. miRNA‐encapsulated abiotic materials and biovectors for cutaneous and oral wound healing: Biogenesis, mechanisms, and delivery nanocarriers. Bioengineering & Translational Medicine 2022, 8: e10343. PMID: 36684081, PMCID: PMC9842058, DOI: 10.1002/btm2.10343.Peer-Reviewed Original Research
2021
Expression of PON2 isoforms varies among brain regions in male and female African green monkeys
Jamwal S, Blackburn JK, Elsworth JD. Expression of PON2 isoforms varies among brain regions in male and female African green monkeys. Free Radical Biology And Medicine 2021, 178: 215-218. PMID: 34890766, PMCID: PMC8760629, DOI: 10.1016/j.freeradbiomed.2021.12.005.Peer-Reviewed Original ResearchConceptsAfrican green monkeysParkinson's diseaseBrain regionsParaoxonase 2Different brain regionsFemale monkeysGreen monkeysPON2 expressionOxidative stress-related neurodegenerative disordersFemale African green monkeysNeurodegenerative disordersMale African green monkeysOxidative stressPON2 protein expressionAnti-inflammatory propertiesExpression levelsSignificant differencesBrain tissue samplesDorsolateral prefrontal cortexNeuroprotective strategiesWestern blotting techniquesDopaminergic neuronsPON2 proteinPrimate brainProtective rolePioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders
Blackburn JK, Jamwal S, Wang W, Elsworth JD. Pioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders. Neurochemistry International 2021, 152: 105222. PMID: 34767873, PMCID: PMC8712400, DOI: 10.1016/j.neuint.2021.105222.Peer-Reviewed Original ResearchConceptsPON2 expressionParkinson's diseaseParaoxonase 2Male African green monkeysShort-term animal modelsOxidative stressPeroxisome proliferator-activated receptor gammaEffect of pioglitazoneWeeks of treatmentProliferator-activated receptor gammaNonhuman primate brainParaoxonase-2 expressionRegion-dependent expressionSex-specific therapeuticsAnti-diabetic drug pioglitazoneAfrican green monkeysDorsolateral prefrontal cortexOral pioglitazonePreclinical evidenceSubstantia nigraClinical trialsPON2 mRNAAnimal modelsPioglitazonePrimate brain